Y.S.H. (3705) Monthly Revenue

Market: TWSE-listed · Industry: Biotech & Medical · 永信

Y.S.H. (3705) reported revenue of NT$749.4 million for Oct 2026, +4.4% year on year and +13.7% from the previous month. Revenue for Jan–Oct 2026 was NT$6.53 billion (-5.8% year on year).

Year-on-year revenue growth: 4 months in a row. →

In Oct 2026, it ranked No. 8 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$744.6 million24/10Nov 2024 NT$693.5 millionDec 2024 NT$726.3 millionJan 2025 NT$738.3 millionFeb 2025 NT$628.1 million25/02Mar 2025 NT$813 millionApr 2025 NT$704.7 millionMay 2025 NT$679.7 millionJun 2025 NT$740.7 million25/06Jul 2025 NT$700.4 millionAug 2025 NT$605.1 millionSep 2025 NT$606.2 millionOct 2025 NT$717.7 million25/10Nov 2025 NT$713.7 millionDec 2025 NT$722 millionJan 2026 NT$697.1 millionFeb 2026 NT$523.5 million26/02Mar 2026 NT$620.2 millionApr 2026 NT$693.9 millionMay 2026 NT$658 millionJun 2026 NT$577.9 million26/06Jul 2026 NT$719.5 millionAug 2026 NT$632.9 millionSep 2026 NT$659.2 millionOct 2026 NT$749.4 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$749.4 million+4.4%+13.7%
Sep 2026NT$659.2 million+8.7%+4.2%
Aug 2026NT$632.9 million+4.6%-12.0%
Jul 2026NT$719.5 million+2.7%+24.5%
Jun 2026NT$577.9 million-22.0%-12.2%
May 2026NT$658 million-3.2%-5.2%
Apr 2026NT$693.9 million-1.5%+11.9%
Mar 2026NT$620.2 million-23.7%+18.5%
Feb 2026NT$523.5 million-16.7%-24.9%
Jan 2026NT$697.1 million-5.6%-3.4%
Dec 2025NT$722 million-0.6%+1.2%
Nov 2025NT$713.7 million+2.9%-0.5%
Oct 2025NT$717.7 million-3.6%+18.4%
Sep 2025NT$606.2 million-1.0%+0.2%
Aug 2025NT$605.1 million-19.1%-13.6%
Jul 2025NT$700.4 million-5.4%-5.4%
Jun 2025NT$740.7 million+17.9%+9.0%
May 2025NT$679.7 million+1.2%-3.5%
Apr 2025NT$704.7 million+3.7%-13.3%
Mar 2025NT$813 million+51.8%+29.4%
Feb 2025NT$628.1 million+18.0%-14.9%
Jan 2025NT$738.3 million+1.3%+1.6%
Dec 2024NT$726.3 million+14.6%+4.7%
Nov 2024NT$693.5 million+0.1%-6.9%
Oct 2024NT$744.6 million+20.5%+21.6%

Jan–Oct 2026 cumulative: NT$6.53 billion (-5.8% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: Y.S.H. vs PEC / Y.S.H. vs Lotus Pharm / Y.S.H. vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
GKB1707NT$748.3 million-30.8%

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16